AbbVie Inc. Files 8-K on Financials
Ticker: ABBV · Form: 8-K · Filed: Oct 31, 2025 · CIK: 1551152
| Field | Detail |
|---|---|
| Company | Abbvie Inc. (ABBV) |
| Form Type | 8-K |
| Filed Date | Oct 31, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: ABBV
TL;DR
AbbVie dropped an 8-K on Oct 31st covering financials. Check it out.
AI Summary
AbbVie Inc. filed an 8-K on October 31, 2025, reporting on its financial condition and results of operations. The filing also includes financial statements and exhibits. AbbVie Inc. is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This filing provides investors with crucial updates on AbbVie's financial performance and condition, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any unusual risks or events.
Key Players & Entities
- AbbVie Inc. (company) — Registrant
- October 31, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 1231 (date) — Fiscal year end
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on AbbVie Inc.'s Results of Operations and Financial Condition, as well as to provide Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 31, 2025.
In which state is AbbVie Inc. incorporated?
AbbVie Inc. is incorporated in Delaware.
What is AbbVie Inc.'s fiscal year end?
AbbVie Inc.'s fiscal year ends on December 31.
What is the SEC file number for AbbVie Inc.?
The SEC file number for AbbVie Inc. is 001-35565.
Filing Stats: 480 words · 2 min read · ~2 pages · Grade level 9.4 · Accepted 2025-10-31 07:51:43
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 Par Value ABBV New York Stock Exchange
Filing Documents
- abbv-20251031.htm (8-K) — 38KB
- abbv-20250930xexhibit991.htm (EX-99.1) — 469KB
- abbvieimage1a53.jpg (GRAPHIC) — 15KB
- 0001551152-25-000047.txt ( ) — 749KB
- abbv-20251031.xsd (EX-101.SCH) — 4KB
- abbv-20251031_def.xml (EX-101.DEF) — 19KB
- abbv-20251031_lab.xml (EX-101.LAB) — 34KB
- abbv-20251031_pre.xml (EX-101.PRE) — 19KB
- abbv-20251031_htm.xml (XML) — 8KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition On October 31, 2025, AbbVie Inc. issued a press release announcing financial results for the third quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Exhibit 99.1 Press Release dated October 31, 2025 (furnished pursuant to Item 2.02). 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABBVIE INC. Date: October 31, 2025 By: /s/ Scott T. Reents Scott T. Reents Executive Vice President, Chief Financial Officer